CJMB

Business Context and Reporting Period

Company: CALLAN JMB INC. (CJMB)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Callan JMB is a vertically integrated logistics and fulfillment company specializing in thermal management solutions for the life sciences industry. The company provides proprietary packaging, information technology (Sentry monitoring), and cold chain logistics for temperature-sensitive products such as cell therapies, vaccines, and biological samples. The company reorganized from a Texas LLC to a Nevada corporation in January 2024 and completed its Initial Public Offering (IPO) in February 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by 50% ($6.64 million) year-over-year. Management attributes this to the waning of the COVID-19 pandemic, reduced demand for emergency preparedness services from government entities, and a significant customer temporarily suspending orders (representing approx. $4 million of 2023 revenue).
• Profitability Reversal: The company swung from a net profit of $2.18 million in 2023 to a net loss of $2.29 million in 2024. Operating income dropped by 203%.
• Expense Increase: Selling, General, and Administrative (SG&A) expenses increased by 40% ($1.39 million). This was driven by:
  • Personnel costs increasing by $508,720 due to the CEO being placed on payroll and hiring staff for the IPO.
  • Consulting and professional fees increasing by $560,796 for capital raising support.
  • Marketing and advertising increasing by $617,116 for investor relations and website redevelopment.
• Liquidity: Cash and cash equivalents decreased by approximately $3.06 million, primarily due to the net loss and partner distributions of $3.33 million.

Guidance, Outlook, Risks, and Unusual Items

• Outlook & Strategy: The company plans to expand into new markets including GLP-1 drug transport, compounding pharmacies, and high-end food packaging. It aims to leverage its "Sentry" monitoring technology to ensure product integrity. Management anticipates continued business from the customer who suspended orders in 2024.
• Unusual Items:
  • Legal Settlement: In February 2025, the company settled a vendor dispute for $240,800. An additional $155,800 was accrued in 2024 expenses to reflect this settlement.
  • Reorganization: The company reorganized from an LLC to a C-Corporation in early 2024, impacting tax provisions and equity structure.
• Risks:
  • Customer Concentration: High concentration risk exists; the top three customers accounted for 81.4% of 2024 revenue (Customer 1: 50.6%).
  • Capital Intensity: The business requires significant capital for warehouse renovations and equipment. The company may need to raise additional capital, potentially diluting shareholders.
  • Internal Controls: Management identified material weaknesses in internal controls, including insufficient staff for segregation of duties and reliance on third-party accounting firms.
  • Regulatory: Subject to extensive FDA, USDA, and DOT regulations regarding the transport of biological and hazardous materials.

Investor Verification Checklist

• Customer Retention: Verify the status of the relationship with "Customer 1" (50.6% of revenue) and the timeline for the resumption of orders from the suspended customer.
• Post-IPO Liquidity: Confirm the utilization of the ~$4.7 million net proceeds from the February 2025 IPO and the company's runway given the 2024 operating loss.
• Internal Controls Remediation: Review the plan and timeline for addressing the identified material weaknesses in internal controls over financial reporting.
• Related Party Transactions: Scrutinize ongoing lease agreements with related parties (e.g., Warehouse Asset Management, Outlaw Run Ranch) to ensure terms are at arm's length.
• Seasonality: Assess the impact of seasonal fluctuations, as revenue is typically highest in Q3 and Q4, on future quarterly performance.